Dramamine

DRAMAMINE*

*Registered Trade mark

Brand of dimenhydrinate

INDICATIONS
Prevention and relief of motion sickness and treatment of vertigo, nausea or vomiting associated with: electro-shock therapy, anaesthesia and surgery, labyrinthine disturbances, radiation sickness, and postfenestration syndrome.

WARNINGS
Caution should be used when DRAMAMINE is given in conjunction with certain antibiotics which may cause ototoxicity, since DRAMAMINE is capable of masking ototoxic symptoms and an irreversible state may be reached.
Although clinical studies in pregnant women have not indicated that DRAMAMINE increases the risk of foetal abnormalities, it, like any drug, should be used during pregnancy only if benefits outweigh the risks. As small amounts of DRAMAMINE are excreted in breast milk, benefits of therapy must be weighed against potential adverse reactions in nursing infants.

ADVERSE REACTIONS
Drowsiness may be experienced by some patients, especially those on high dosage, although this effect frequently is not undersirable in some conditions for which the drug is used. However, patients should be cautioned against operating automobiles or dangerous machinery while taking DRAMAMINE because of possible drug-associated drowsiness

DOSAGE AND ADMINISTRATION
Tablets
DRAMAMINE is available as a 50 mg tablet..
Adults:
The adult therapeutic and prophylactic dose is 50 to 100 mg three or four times daily.
Children :
Ages 6-8 years : 12.5 mg to 25 mg (¼ to ½ tablet) two or three times daily.
Ages 8-12 years : 25 mg to 50 mg (½ to one tablet) two or three times daily.
Ages 12 years or older : 50 mg (one tablet) two or three times daily.
For prevention of motion sickness the first dose should be given 30 minutes before departure.

PRESENTATION
Tablets 50 mg, yellow, scored, uncoated, stamped "Searle" on one side, in packs of 100.
Reg No. DL.2012159.

Manufactured in Indonesia under licence by
PT SOHO INDUSTRI PHARMASI, JAKARTA - INDONESIA

Searle,
Division of Monsanto Australia Limited
Sydney, Australia.

Share this :